Pharmacological profile of the 5-HT2c receptor agonist WAY-163909;: Therapeutic potential in multiple indications

被引：70

作者：

Dunlop, John ^{[1
]}

Marquis, Karen L. ^{[1
]}

Lim, H. K. ^{[1
]}

Leung, Louis ^{[1
]}

Kao, John ^{[1
]}

Cheesman, Cynthia ^{[1
]}

Rosenzweig-Lipson, Sharon ^{[1
]}

机构：

[1] Wyeth Res, Discovery Neurosci, Princeton, NJ 08543 USA

来源：

CNS DRUG REVIEWS | 2006年 / 12卷 / 3-4期

关键词：

5-HT2C receptors; depression; obesity; schizophrenia; serotonin; WAY-163909;

D O I：

10.1111/j.1527-3458.2006.00167.x

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The 5-HT2C receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery. Here we review the pharmacological, pharmacokinetic and toxicological profile of WAY-163909 {(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole}, a novel 5-HT2C receptor selective agonist. Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression.

引用

页码：167 / 177

页数：11

共 35 条

[1] A review of central 5-HT receptors and their function [J].

Barnes, NM ;

Sharp, T .

NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152

[2]

BERENDSEN HHG, 1995, PHARMACOL THERAPEUT, V66, P17, DOI 10.1016/0163-7258(94)00075-E

[3]

BICKERDIKE MJ, 2002, 5 IUPHAR SAT M SER

[4] Novel agonists of 5HT(2C) receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder [J].

Bos, M ;

Jenck, F ;

Martin, JR ;

Moreau, JL ;

Sleight, AJ ;

Wichmann, J ;

Widmer, U .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (17) :2762-2769

[5] HYPOPHAGIC, ENDOCRINE AND SUBJECTIVE RESPONSES TO M-CHLOROPHENYLPIPERAZINE IN HEALTHY-MEN AND WOMEN [J].

COWEN, PJ ;

SARGENT, PA ;

WILLIAMS, C ;

GOODALL, EM ;

ORLIKOV, AB .

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1995, 10 (05) :385-391

[6] Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected? [J].

Cryan, JF ;

McGrath, C ;

Leonard, BE ;

Norman, TR .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 352 (01) :23-28

[7] BLOCKADE OF THE ANTIDEPRESSANT-LIKE EFFECTS OF 8-OH-DPAT, BUSPIRONE AND DESIPRAMINE IN THE RAT FORCED SWIM TEST BY 5HT(1A) RECEPTOR ANTAGONISTS [J].

DETKE, MJ ;

WIELAND, S ;

LUCKI, I .

PSYCHOPHARMACOLOGY, 1995, 119 (01) :47-54

[8] WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity [J].

Dunlop, J ;

Sabb, AL ;

Mazandarani, H ;

Zhang, J ;

Kalgaonker, S ;

Shukhina, E ;

Sukoff, S ;

Vogel, RL ;

Stack, G ;

Schechter, L ;

Harrison, BL ;

Rosenzweig-Lipson, S .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (02) :862-869

[9] 5-HT1C RECEPTOR ACTIVATION - A KEY STEP IN THE INITIATION OF MIGRAINE [J].

FOZARD, JR ;

GRAY, JA .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (08) :307-309

[10] EVIDENCE THAT MCPP-INDUCED ANXIETY IN THE PLUS-MAZE IS MEDIATED BY POSTSYNAPTIC 5-HT2C RECEPTORS BUT NOT BY SYMPATHOMIMETIC EFFECTS [J].

GIBSON, EL ;

BARNFIELD, AMC ;

CURZON, G .

NEUROPHARMACOLOGY, 1994, 33 (3-4) :457-465

← 1 2 3 4 →